ProUroCare Medical (PUMD) Stock Price, News & Analysis

Company Overview

ProUroCare Medical, Inc. is a development‐stage medical device company focused on advancing minimally invasive diagnostic and therapeutic solutions for urological conditions. The company’s research and development efforts center on technologies intended to address lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH) and pelvic floor disorders, including urinary incontinence. ProUroCare aims to improve patient outcomes by offering alternatives to traditional surgical and pharmaceutical approaches.

ProUroCare’s product portfolio is currently in preclinical and early clinical stages, with the company working toward securing regulatory clearances in the United States. Its development strategy emphasizes collaborative partnerships with urology specialists, academic research centers and clinical sites to conduct feasibility studies and pivotal trials. By aligning with established healthcare institutions, ProUroCare seeks to generate robust clinical data and accelerate time to market for its lead device candidates.

Headquartered in the United States, ProUroCare serves a primarily domestic patient base while evaluating opportunities to expand into select international markets in Europe and Asia. The company’s go‐to‐market plan includes building a direct sales force focused on urology centers of excellence and exploring distribution agreements to broaden reach. ProUroCare also maintains ongoing dialogues with reimbursement experts to ensure appropriate coverage and payment pathways for its future therapies.

ProUroCare is led by a management team and board of directors with experience in medical device innovation, regulatory affairs and commercial operations. Drawing on decades of combined expertise in product development, quality systems and clinical research, the leadership team is tasked with steering the company through pivotal development milestones and positioning it for long-term growth in the urology market. Markets OTCMKTS:PUMD

Key Stats

• Today's Range: $0.0002 to $0.0002
• 50-Day Range: N/A
• 52-Week Range: $0.0002 to $0.0002
• Volume: N/A
• Average Volume: 2,166 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PUMD Stock Analysis - Frequently Asked Questions

How have PUMD shares performed this year?

ProUroCare Medical's stock was trading at $0.0002 on January 1st, 2025. Since then, PUMD shares have increased by 0.0% and is now trading at $0.0002.

How do I buy shares of ProUroCare Medical?

Shares of PUMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 10/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:PUMD
• CIK: 1222244
• Web: www.prourocare.com
• Phone: (952) 476-9093
• Fax: 952-843-7031
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: -15.27